Development of Nanoparticle Drug Delivery Systems for Stroke Treatment

Nanoparticles have many advantages for delivering drugs to the brain. More and more research suggested that these advantages are not simply summed up in the small size of nanoparticles. Studies have shown that lipid nanoparticles, polymer nanoparticles, silica nanoparticles, magnetic nanoparticles, and other nanoparticles are highly suitable for brain delivery, which depends on properties such as size, surface charge, the morphology of the nanoparticle, especially molecular recognition and interaction between specific ligands bound on the nanoparticle surface and molecules overexpressed on the brain target (active targeting). Ace Therapeutics offers a range of services to develop nanoparticle drug delivery systems for stroke treatment.

Development of Nanoparticle Drug Delivery Systems for Stroke Treatment

Characterization of Nanomaterials

Selecting and identifying suitable nanomaterials is very important for constructing a nanomaterial delivery system. Therefore, Ace Therapeutics provides different ways to identify nanoparticles.

  • The morphology and structure of nanomaterials are characterized by SEM, TEM, AFM, microCT, X-ray diffraction, and other assays.
  • The physicochemical properties of nanomaterials are tested by UV-VIS absorption spectroscopy, FTIR infrared spectroscopy, FS fluorescence spectroscopy, SERS Raman spectroscopy, VSM vibrating sample magnetometer, and other assays.
  • The composition of nanomaterials is analyzed by X-ray photoelectron spectroscopy, ICP inductively coupled plasma direct reading spectroscopy, elemental analysis, thermogravimetric analysis, SEM electron spectroscopy, and other assays.

Development Services of Nanoparticle Drug Delivery Systems for Stroke Treatment

Given the multiple advantages of nanoparticles for brain targeted drug delivery, Ace Therapeutics provides comprehensive services to facilitate the development of nanoparticle drug delivery systems for stroke treatment, including nanoparticle design, nanoparticle distribution detection, drug encapsulation, and in vitro and in vivo metabolic studies.

  • Designing particles with different size ranges
  • Detecting particle size distribution
    High resolution capability throughout the measurement range
    The measurement method is robust, simple, and fast
    The non-contact measurement method is adopted
    In situ measurement of particle size over time
  • Capability to control and program drug release
    Zero-order kinetics
    Release in several time-stages
    Release in several speed ranges
  • Resolving encapsulation problems

Measurement of Blood Brain Barrier Permeability

Ace Therapeutics provides comprehensive services to measure the ability of nanomedicines to cross the BBB while performing pharmacokinetic testing of nanomedicines.

  • We have developed in vitro and in vivo models of the BBB to evaluate the ability of nanomedicine to penetrate the BBB.
  • We perform pharmacokinetic analysis of nanomedicine, including internal clearance rate and external clearance rate, brain / blood partition coefficient, drug brain tissue distribution volume, and intracerebral half-life.

If you would like to learn more about our services, please feel free to contact us.

  1. Pinheiro, R. G. R., et al., Nanoparticles for targeted brain drug delivery: What do we know? Int J Mol Sci, 2021. 22(21).
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket